How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
43
GOSS Quote, Financials, Valuation and Earnings
Last price:
$2.28
Seasonality move
:
-15.26%
Day range:
$2.27 - $2.47
52-week range:
$0.76 - $3.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.76x
P/B ratio:
8.01x
Volume:
4.6M
Avg. volume:
4.9M
1-year change:
136.59%
Market cap:
$527.7M
Revenue:
$114.7M
EPS (TTM):
-$0.69
Analysts' Opinion
-
Consensus RatingGossamer Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.43, Gossamer Bio, Inc. has an estimated upside of 313.53% from its current price of $2.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $2.28.
Fair Value
-
According to the consensus of 7 analysts, Gossamer Bio, Inc. has 313.53% upside to fair value with a price target of $9.43 per share.
GOSS vs. S&P 500
-
Over the past 5 trading days, Gossamer Bio, Inc. has underperformed the S&P 500 by -15.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Gossamer Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gossamer Bio, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Gossamer Bio, Inc. reported revenues of $13.3M.
Earnings Growth
-
Gossamer Bio, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Gossamer Bio, Inc. reported earnings per share of -$0.21.
Enterprise value:
550.4M
EV / Invested capital:
--
Price / LTM sales:
11.76x
EV / EBIT:
--
EV / Revenue:
12.49x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-3.47x
Price / Operating cash flow:
54.59x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$42.2M
Return On Assets:
-55.91%
Net Income Margin (TTM):
-354.5%
Return On Equity:
-615%
Return On Invested Capital:
-81%
Operating Margin:
-313.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $105.3M | $44.1M | $9.5M | $13.3M | |
| Gross Profit | -$4.5M | $101.3M | $42.2M | $8.4M | $13.1M | |
| Operating Income | -$189M | -$62.8M | -$153.3M | -$33.9M | -$41.6M | |
| EBITDA | -$184.5M | -$58.8M | -$151.5M | -$32.8M | -$41.4M | |
| Diluted EPS | -$1.76 | -$0.33 | -$0.69 | -$0.14 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $374M | $312M | $341.5M | $344.3M | $204M | |
| Total Assets | $387M | $323.5M | $347.9M | $350.9M | $208.8M | |
| Current Liabilities | $35.9M | $52.6M | $42.3M | $51.1M | $62.1M | |
| Total Liabilities | $217.2M | $267.2M | $243.3M | $296.7M | $291.2M | |
| Total Equity | $169.8M | $56.4M | $104.6M | $54.1M | -$82.3M | |
| Total Debt | $184.4M | $226.2M | $212.6M | $201.9M | $202M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$173.5M | -$1.4M | -$158.4M | -$32M | -$36.2M | |
| Cash From Investing | -$88.1M | -$38.6M | $136.4M | -$26.8M | $17M | |
| Cash From Financing | $190.2M | -$14.4M | $2.5M | $281K | $1.9M | |
| Free Cash Flow | -$173.6M | -$1.4M | -$158.5M | -$32M | -$36.2M | |
GOSS
Sector
Market Cap
$527.7M
$24.3M
Price % of 52-Week High
58.92%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.54%
-1.67%
1-Year Price Total Return
136.59%
-21.43%
Beta (5-Year)
1.922
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.61
200-day SMA
Buy
Level
$2.16
Bollinger Bands (100)
Sell
Level
2.4 - 3.26
Chaikin Money Flow
Sell
Level
-7.9M
20-day SMA
Sell
Level
$2.60
Relative Strength Index (RSI14)
Sell
Level
34.25
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-98.6283
50-day SMA
Sell
Level
$3.04
MACD (12, 26)
Buy
Level
0.33
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-9.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4577)
Sell
CA Score
(Annual)
Level (-2.8036)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2862)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, GOSS has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GOSS average analyst price target in the past 3 months is $9.43.
-
Where Will Gossamer Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gossamer Bio, Inc. share price will rise to $9.43 per share over the next 12 months.
-
What Do Analysts Say About Gossamer Bio, Inc.?
Analysts are divided on their view about Gossamer Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gossamer Bio, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Gossamer Bio, Inc.'s Price Target?
The price target for Gossamer Bio, Inc. over the next 1-year time period is forecast to be $9.43 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GOSS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gossamer Bio, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GOSS?
You can purchase shares of Gossamer Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gossamer Bio, Inc. shares.
-
What Is The Gossamer Bio, Inc. Share Price Today?
Gossamer Bio, Inc. was last trading at $2.28 per share. This represents the most recent stock quote for Gossamer Bio, Inc.. Yesterday, Gossamer Bio, Inc. closed at $2.28 per share.
-
How To Buy Gossamer Bio, Inc. Stock Online?
In order to purchase Gossamer Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GOSS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GOSS
Sector
P/E ratio
--
23.33x
PEG ratio
-0.03x
-0.01x
P/B ratio
8.01x
1.78x
Price / LTM sales
11.76x
1.53x
Growth Metrics
GOSS
Sector
Revenue growth
40.23%
4%
Earnings growth
-55.4%
11.06%
Revenue (5-year growth)
--
6.22%
Earnings forecast
-$0.18
-$0.19
Profitability
GOSS
Sector
Profitability FY 2024
$110.6M
$3M
Return on invested capital
-81%
-33.25%
Return on assets
-55.91%
-29.67%
Return on equity
-615%
-38.89%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
4
Balance Sheet
GOSS
Sector
Total cash
$180.2M
$25M
Short term investments
$248.4M
$24.9M
Total assets
$315.3M
$72.5M
Long term debt
$202M
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
